Related Experiment Video
Updated: May 17, 2026

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
New therapeutic options for HCV infection in the monoclonal antibody era
Giuseppe Andrea Sautto1, Roberta Antonia Diotti, Massimo Clementi
1Laboratory of Microbiology and Virology, Universita Vita-Salute San Raffaele, Milano, Italy. sautto.giuseppe@hsr.it
Abstract:
Hepatitis C virus (HCV) infection is a leading cause of chronic liver disease and the most common indication for liver transplantation. Current therapies are ineffective in a relevant percentage of patients raising the urgent medical need to develop adequate therapies for this infection. Broadly neutralizing human monoclonal antibodies (mAbs) directed against the HCV E2 glycoprotein (HCV/E2), the major target of the neutralizing humoral immune response, are considered as a possible novel therapeutic strategy for this infection. In the last few years, several anti-HCV/E2 human mAbs have been described in literature to be possibly used for therapeutic or prophylactic purposes. In this review, we illustrate the best candidates for an anti-HCV mAb-based therapy, considering their cross-neutralization profiles and their ability to overcome possible viral escape mechanisms.
More Related Videos
Related Concept Videos
Retrovirus Life Cycles
Hybridoma Technology
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Inhibitors of Viral Protein Synthesis
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Hepatitis
Tumor Immunotherapy

